GR 46611 is a selective 5-HT1B and 5-HT1D receptor agonist and can be used in studies about the treatment of epilepsy.

GR 46611 (0.6 and 6 nmol; paraventricular hypothalamic nucleus (PVN)) promptly and reliably elicited feeding at their higher doses, without affecting drinking or non-ingestive behaviors. GR 46611 (6 nmol) elicited intense feeding responses in the n. medialis hypothalami posterioris and in the adjacent n. lateralis hypothalami posterioris (PMH/PLH complex, in the caudoventral hypothalamus) and in the n. magnocellularis preopticus (PPM, in the caudal preoptic region)[1]. GR 46611 (1 mg/kg) significantly increased the threshold of hyperthermia-induced seizure and lowered seizure severity thereby improving the survival of DS mice[2].